3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Interventions
Rituximab
48
Cyclophosphamide
27
Lenalidomide
23
Peripheral Blood Stem Cell Transplantation
16
obinutuzumab
10
fludarabine phosphate
10
Filgrastim
10
Etoposide
10
Bendamustine Hydrochloride
10
Vincristine
8
Prednisone
8
Doxorubicin
8
fludarabine
7
Radiotherapy
7
Mycophenolic Acid
7
Melphalan
7
Cyclosporine
7
Bortezomib
7
venetoclax
6
tazemetostat
6
ibritumomab tiuxetan
6
Whole-Body Irradiation
6
Gemcitabine
6
pembrolizumab
5
ibrutinib
5
Ifosfamide
5
Granulocyte Colony-Stimulating Factor
5
CT-P10
5
veltuzumab
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Follicular
×
Maintenance
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled